Trubrexa: US FDA label indications
US FDA labelNot medical advice
Label details
- Brand name
- Trubrexa
- Generic name
- Lidocaine And Capsaicin
- Manufacturer
- Strand Health Group
- Route
- Transdermal
- Product type
- Human Prescription Drug
- Substance
- Capsaicin
Indications and usage (label excerpt)
1. INDICATIONS & USAGE Trubrexa TM Transdermal Patch is indicated in adults over the age of 12 years old for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more.
Warnings (label excerpt)
5. WARNINGS, PRECAUTIONS & ADVERSE REACTIONS 5.1 Risk of Methemoglobinemia Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; fatigue; or lightheadedness. Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monito…
Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).
Trials whose interventions mention this drug
Canadian trials first. A match on the drug name does not mean the trial studied this specific product.
10 trials, recruiting first
Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.